Compare iShares Semiconductor ETF (SOXX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Semiconductor ETF vs Tango Therapeutics Inc. — how do they compare? iShares Semiconductor ETF trades at $510.53 (market cap $44.53B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares Semiconductor ETF is far larger — about 11.9× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 8,354,155). Which is the better fit depends on your goals — on Pluang, investors hold iShares Semiconductor ETF for 47 Days and Tango Therapeutics Inc. for 0 Days on average.
| SOXX | TNGX | |
|---|---|---|
Market Cap | $44.53B | $3.75B |
Volume | 8,354,155 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $655.01 | $32.90 |
52-Week Low | $268.10 | $7.50 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXX trades at $543.9, down 0.17% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The semiconductor ETF faces mixed sentiment with strong AI-driven earnings growth projections but elevated valuation concerns. Recent news highlights Michael Burry's expanded short position while other analysts point to continued earnings momentum supporting the sector.
The semiconductor sector outlook remains bifurcated between strong AI-driven fundamentals and valuation risks. SOXX's investment case hinges on sustained AI infrastructure demand, though current technical weakness and high multiples relative to broader markets warrant caution. Key risks include sector concentration and potential AI development slowdowns.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
